Roche, Pfizer, Sanofi Plan $72.7 Million Stem-Cell Bank
This article is for subscribers only.
Drug companies and universities are spending 55.6 million euros ($72.7 million) to develop a bank of stem cells to use in testing potential treatments for hard-to-treat diseases.
The effort, known as Stembancc and managed by the University of Oxford in England, will focus on generating 1,500 induced pluripotent stem cell lines, researchers said at a London news conference. The cells will be used by drugmakers including Pfizer Inc., Sanofi and Roche Holding AG to test treatments for peripheral nervous disorders, pain, dementia, migraine, autism, schizophrenia, bipolar disorder and diabetes and to perform toxicology tests.